BlackRock’s IBIT is making history as it nears $100 billion in Asset Under Management (AUM), becoming one of the few out of the over 4,500 ETFs to achieve this milestone.  An analyst has labeled the 2025 Bitcoin rally as the most structured in its history and predicts a run to at least $130,000.  Bloomberg ETF [...]]]>BlackRock’s IBIT is making history as it nears $100 billion in Asset Under Management (AUM), becoming one of the few out of the over 4,500 ETFs to achieve this milestone.  An analyst has labeled the 2025 Bitcoin rally as the most structured in its history and predicts a run to at least $130,000.  Bloomberg ETF [...]]]>

BlackRock’s Bitcoin ETF Nears $100B, Becomes Firm’s Most Profitable Product

2025/10/08 17:28
  • BlackRock’s IBIT is making history as it nears $100 billion in Asset Under Management (AUM), becoming one of the few out of the over 4,500 ETFs to achieve this milestone. 
  • An analyst has labeled the 2025 Bitcoin rally as the most structured in its history and predicts a run to at least $130,000. 

Bloomberg ETF analyst Eric Balchunas has hinted that the iShares Bitcoin Trust ETF (iBIT) has now become the most profitable ETF for BlackRock. According to the analyst, it is just some $2 billion away from becoming the fastest ETF to reach $100 billion in total Asset Under Management, as discussed in our previous news story.

BlackRock

Details of BlackRock’s IBIT Incredible Run

In a post, Balchunas lauded this impressive feat, highlighting that the Vanguard S&P 500 ETF needed 2,011 days to reach its current best. Meanwhile, IBIT is achieving this in just 435 days. As mentioned in our previous news brief, the IBIT’s AUM was around $70 billion in June, and had outpaced Gold’s ETF by 5 times.

Based on our research, BlackRock’s IBIT held about 783,767.84 BTC as of October 3. Days ago, 7,860 BTC was added, taking the total to 791,628 BTC. At Bitcoin’s daily high of $125k, its holding was worth almost $99 billion. According to Balchunas, IBIT also leads the company’s funds by annual revenue.

Overall, the US spot Bitcoin ETFs have had some impressive numbers since their inception in January 2024, recording a net inflow of around $61.5 billion. In total, the Asset Under Management is now around $170 billion. Fascinatingly, BlackRock’s performance so far has received applause from multiple experts.

According to NovaDius Wealth Management President Nate Geraci, only 18 out of the more than 4,500 ETFs have been able to achieve $100 billion AUM. To appreciate this even more, Geraci pointed out that the first ETF emerged in 1993, implying that BlackRock has attained a feat only a few could ever dream of in the industry’s 32-year history.

Bitcoin’s 2025 Performance

Commenting on the recent Bitcoin price, BRN Head of Research Timothy Misir has noted that the Bitcoin rally recorded this year is so far the most structured in its history.

While he confirms that there is a short-term overheating risk, he also admitted that the market has seen sustained real demand. In the meantime, he expects the price to hover within the $123,000 and $126,000 range before breaking out to between $130,000 and $135,000.

Our recent analysis also shows that Bitcoin has already entered a pre-euphoria phase. Meanwhile, 63% of analyst Plan B’s followers believe that Bitcoin could fall to below $100k at some point, as noted in our recent publication.

]]>
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?

RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?

The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans…
Share
BitcoinEthereumNews2025/09/26 19:16
Share